Clin Nutr Res.  2015 Jul;4(3):182-189. 10.7762/cnr.2015.4.3.182.

Dietary Very Long Chain Saturated Fatty Acids and Metabolic Factors: Findings from the Korea National Health and Nutrition Examination Survey 2013

Affiliations
  • 1Department of Food and Nutrition, Korea University, Seoul 136-701, Korea. mjshin@korea.ac.kr
  • 2Department of Public Health Science, BK21PLUS Program in Embodiment: Health-Society Interaction, Graduate School of Korea University, Seoul 136-701, Korea.
  • 3Korea University Guro Hospital, Korea University College of Medicine, Seoul 152-703, Korea.

Abstract

The present study was aim to evaluate the association between very long chain saturated fatty acids (VLSFAs) and metabolic syndrome (MetS) in Korean population. The study population were recruited from the Korea National Health and Nutrition Examination Survey VI (2013). Using the cross-sectional study design, socio-demographic factors, medical history, and clinical measurements were investigated according to quartiles of VLSFAs intake. The associations between each and sum of VLSFAs intake and MetS were assessed by logistic regression. The result indicated that higher intake of VLSFAs was significantly associated with favorable metabolic status, including lower levels of circulating triglyceride (TG) (p < 0.05). Additionally, subjects with higher intake of arachidic acid and total VLSFAs were negatively associated with MetS risk compared to subjects with lower intake of those fatty acids (p < 0.05). In conclusion, dietary VLSFAs intake was associated with metabolic risk factors and lower risk of MetS in Korean population.

Keyword

Fatty acid; Metabolic syndrome; Arachidic acid; Behenic acid; Lignoceric acid

MeSH Terms

Cross-Sectional Studies
Fatty Acids*
Korea*
Logistic Models
Nutrition Surveys*
Risk Factors
Triglycerides
Fatty Acids

Reference

1. Matsumori R, Miyazaki T, Shimada K, Kume A, Kitamura Y, Oshida K, Yanagisawa N, Kiyanagi T, Hiki M, Fukao K, Hirose K, Ohsaka H, Mokuno H, Daida H. High levels of very long-chain saturated fatty acid in erythrocytes correlates with atherogenic lipoprotein profiles in subjects with metabolic syndrome. Diabetes Res Clin Pract. 2013; 99:12–18.
Article
2. Mozumdar A, Liguori G. Persistent increase of prevalence of metabolic syndrome among U.S. adults: NHANES III to NHANES 1999-2006. Diabetes Care. 2011; 34:216–219.
Article
3. Lim S, Shin H, Song JH, Kwak SH, Kang SM, Won Yoon J, Choi SH, Cho SI, Park KS, Lee HK, Jang HC, Koh KK. Increasing prevalence of metabolic syndrome in Korea: the Korean National Health and Nutrition Examination Survey for 1998-2007. Diabetes Care. 2011; 34:1323–1328.
4. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005; 365:1415–1428.
Article
5. Lee S, Do HJ, Kang SM, Chung JH, Park E, Shin MJ. Plasma phospholipid fatty acid composition and estimated desaturase activity in heart failure patients with metabolic syndrome. J Clin Biochem Nutr. 2012; 51:150–155.
Article
6. Kim OY, Lim HH, Lee MJ, Kim JY, Lee JH. Association of fatty acid composition in serum phospholipids with metabolic syndrome and arterial stiffness. Nutr Metab Cardiovasc Dis. 2013; 23:366–374.
Article
7. Do HJ, Chung HK, Moon J, Shin MJ. Relationship between the estimates of desaturase activities and cardiometabolic phenotypes in Koreans. J Clin Biochem Nutr. 2011; 49:131–135.
Article
8. Laaksonen DE, Lakka TA, Lakka HM, Nyyssönen K, Rissanen T, Niskanen LK, Salonen JT. Serum fatty acid composition predicts development of impaired fasting glycaemia and diabetes in middle-aged men. Diabet Med. 2002; 19:456–464.
Article
9. Zheng ZJ, Folsom AR, Ma J, Arnett DK, McGovern PG, Eckfeldt JH. Plasma fatty acid composition and 6-year incidence of hypertension in middle-aged adults: the Atherosclerosis Risk in Communities (ARIC) Study. Am J Epidemiol. 1999; 150:492–500.
Article
10. Kim YS, Xun P, He K. Fish consumption, long-chain omega-3 polyunsaturated fatty acid intake and risk of metabolic syndrome: a metaanalysis. Nutrients. 2015; 7:2085–2100.
Article
11. Mayneris-Perxachs J, Sala-Vila A, Chisaguano M, Castellote AI, Estruch R, Covas MI, Fitó M, Salas-Salvadó J, Martínez-González MA, Lamuela-Raventós R, Ros E, López-Sabater MC. PREDIMED Study Investigators. Effects of 1-year intervention with a Mediterranean diet on plasma fatty acid composition and metabolic syndrome in a population at high cardiovascular risk. PLoS One. 2014; 9:e85202.
Article
12. Summers LK, Fielding BA, Bradshaw HA, Ilic V, Beysen C, Clark ML, Moore NR, Frayn KN. Substituting dietary saturated fat with polyunsaturated fat changes abdominal fat distribution and improves insulin sensitivity. Diabetologia. 2002; 45:369–377.
Article
13. Shin MJ, Shim E, Kang B, Park S, Lee SH, Shim CY, Park E, Chung N. Increased inflammation, reduced plasma phospholipid eicosapentaenoic acid and reduced antioxidant potential of treated hypertensive patients with metabolic syndrome. Yonsei Med J. 2009; 50:757–763.
Article
14. Kim YJ, Kim OY, Cho Y, Chung JH, Jung YS, Hwang GS, Shin MJ. Plasma phospholipid fatty acid composition in ischemic stroke: importance of docosahexaenoic acid in the risk for intracranial atherosclerotic stenosis. Atherosclerosis. 2012; 225:418–424.
Article
15. van Dijk SJ, Feskens EJ, Bos MB, Hoelen DW, Heijligenberg R, Bromhaar MG, de Groot LC, de Vries JH, Müller M, Afman LA. A saturated fatty acid-rich diet induces an obesity-linked proinflammatory gene expression profile in adipose tissue of subjects at risk of metabolic syndrome. Am J Clin Nutr. 2009; 90:1656–1664.
Article
16. Xiao C, Giacca A, Carpentier A, Lewis GF. Differential effects of monounsaturated, polyunsaturated and saturated fat ingestion on glucose-stimulated insulin secretion, sensitivity and clearance in overweight and obese, non-diabetic humans. Diabetologia. 2006; 49:1371–1379.
Article
17. French MA, Sundram K, Clandinin MT. Cholesterolaemic effect of palmitic acid in relation to other dietary fatty acids. Asia Pac J Clin Nutr. 2002; 11:S401–S407.
Article
18. Hodson L, Skeaff CM, Fielding BA. Fatty acid composition of adipose tissue and blood in humans and its use as a biomarker of dietary intake. Prog Lipid Res. 2008; 47:348–380.
Article
19. Matsumoto C, Hanson NQ, Tsai MY, Glynn RJ, Gaziano JM, Djoussé L. Plasma phospholipid saturated fatty acids and heart failure risk in the Physicians' Health Study. Clin Nutr. 2013; 32:819–823.
Article
20. Lemaitre RN, Fretts AM, Sitlani CM, Biggs ML, Mukamal K, King IB, Song X, Djoussé L, Siscovick DS, McKnight B, Sotoodehnia N, Kizer JR, Mozaffarian D. Plasma phospholipid very-long-chain saturated fatty acids and incident diabetes in older adults: the Cardiovascular Health Study. Am J Clin Nutr. 2015; 101:1047–1054.
Article
21. Fretts AM, Mozaffarian D, Siscovick DS, Djousse L, Heckbert SR, King IB, McKnight B, Sitlani C, Sacks FM, Song X, Sotoodehnia N, Spiegelman D, Wallace ER, Lemaitre RN. Plasma phospholipid saturated fatty acids and incident atrial fibrillation: the Cardiovascular Health Study. J Am Heart Assoc. 2014; 3:e000889.
Article
22. Forouhi NG, Koulman A, Sharp SJ, Imamura F, Kröger J, Schulze MB, Crowe FL, Huerta JM, Guevara M, Beulens JW, van Woudenbergh GJ, Wang L, Summerhill K, Griffin JL, Feskens EJ, Amiano P, Boeing H, Clavel-Chapelon F, Dartois L, Fagherazzi G, Franks PW, Gonzalez C, Jakobsen MU, Kaaks R, Key TJ, Khaw KT, Kühn T, Mattiello A, Nilsson PM, Overvad K, Pala V, Palli D, Quirós JR, Rolandsson O, Roswall N, Sacerdote C, Sánchez MJ, Slimani N, Spijkerman AM, Tjonneland A, Tormo MJ, Tumino R, van der A DL, van der Schouw YT, Langenberg C, Riboli E, Wareham NJ. Differences in the prospective association between individual plasma phospholipid saturated fatty acids and incident type 2 diabetes: the EPIC-InterAct case-cohort study. Lancet Diabetes Endocrinol. 2014; 2:810–818.
Article
23. Kweon S, Kim Y, Jang MJ, Kim Y, Kim K, Choi S, Chun C, Khang YH, Oh K. Data resource profile: the Korea National Health and Nutrition Examination Survey (KNHANES). Int J Epidemiol. 2014; 43:69–77.
Article
24. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972; 18:499–502.
Article
25. Rural Development Administration (KR). Food composition table. 7th ed. Suwon: Rural Development Administration;2006.
26. World Health Organization Western Pacific Region (PH). International Association for the Study of Obesity (GB). International Obesity Task Force (GB). The Asia-Pacific perspective: redefining obesity and its treatment. Balmain: Health Communications Australia;2000.
27. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F. American Heart Association. National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005; 112:2735–2752.
28. United States Department of Agriculture, Agricultural Research Service. USDA National Nutrient Database for Standard Reference: Release 27 [Internet]. 2015. cited 2015 June 11. Available from http://www.ars.usda.gov/Services/docs.htm?docid=8964.
29. Lam C, Wong D, Cederbaum S, Lim B, Qu Y. Peanut consumption increases levels of plasma very long chain fatty acids in humans. Mol Genet Metab. 2012; 107:620–622.
Article
30. Garg ML, Blake RJ, Wills RB. Macadamia nut consumption lowers plasma total and LDL cholesterol levels in hypercholesterolemic men. J Nutr. 2003; 133:1060–1063.
Article
31. Griel AE, Cao Y, Bagshaw DD, Cifelli AM, Holub B, Kris-Etherton PM. A macadamia nut-rich diet reduces total and LDL-cholesterol in mildly hypercholesterolemic men and women. J Nutr. 2008; 138:761–767.
Article
32. Lemaitre RN, King IB, Rice K, McKnight B, Sotoodehnia N, Rea TD, Johnson CO, Raghunathan TE, Cobb LA, Mozaffarian D, Siscovick DS. Erythrocyte very long-chain saturated fatty acids associated with lower risk of incident sudden cardiac arrest. Prostaglandins Leukot Essent Fatty Acids. 2014; 91:149–153.
Article
33. Kim NH, Ahn Y, Oh SK, Cho JK, Park HW, Kim YS, Hong MH, Nam KI, Park WJ, Jeong MH, Ahn BH, Choi JB, Kook H, Park JC, Jeong JW, Kang JC. Altered patterns of gene expression in response to chronic atrial fibrillation. Int Heart J. 2005; 46:383–395.
Article
34. Kröger J, Zietemann V, Enzenbach C, Weikert C, Jansen EH, Döring F, Joost HG, Boeing H, Schulze MB. Erythrocyte membrane phospholipid fatty acids, desaturase activity, and dietary fatty acids in relation to risk of type 2 diabetes in the European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Am J Clin Nutr. 2011; 93:127–142.
Article
35. Lauritzen L, Hellgren LI. Plasma phospholipid very-long-chain saturated fatty acids: a sensitive marker of metabolic dysfunction or an indicator of specific healthy dietary components? Am J Clin Nutr. 2015; 101:901–902.
Article
36. Kihara A. Very long-chain fatty acids: elongation, physiology and related disorders. J Biochem. 2012; 152:387–395.
Article
37. Mesicek J, Lee H, Feldman T, Jiang X, Skobeleva A, Berdyshev EV, Haimovitz-Friedman A, Fuks Z, Kolesnick R. Ceramide synthases 2, 5, and 6 confer distinct roles in radiation-induced apoptosis in HeLa cells. Cell Signal. 2010; 22:1300–1307.
Article
38. Turpin SM, Nicholls HT, Willmes DM, Mourier A, Brodesser S, Wunderlich CM, Mauer J, Xu E, Hammerschmidt P, Brönneke HS, Trifunovic A, LoSasso G, Wunderlich FT, Kornfeld JW, Blüher M, Krönke M, Brüning JC. Obesity-induced CerS6-dependent C16:0 ceramide production promotes weight gain and glucose intolerance. Cell Metab. 2014; 20:678–686.
Article
39. Raichur S, Wang ST, Chan PW, Li Y, Ching J, Chaurasia B, Dogra S, Öhman MK, Takeda K, Sugii S, Pewzner-Jung Y, Futerman AH, Summers SA. CerS2 haploinsufficiency inhibits β-oxidation and confers susceptibility to diet-induced steatohepatitis and insulin resistance. Cell Metab. 2014; 20:687–695.
Article
40. Pewzner-Jung Y, Park H, Laviad EL, Silva LC, Lahiri S, Stiban J, Erez-Roman R, Brügger B, Sachsenheimer T, Wieland F, Prieto M, Merrill AH Jr, Futerman AH. A critical role for ceramide synthase 2 in liver homeostasis: I. alterations in lipid metabolic pathways. J Biol Chem. 2010; 285:10902–10910.
Full Text Links
  • CNR
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr